174 related articles for article (PubMed ID: 32373524)
21. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
22. Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies.
Rassek K; Iżykowska K
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751918
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
24. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
Elenitoba-Johnson KS; Wilcox R
Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
[TBL] [Abstract][Full Text] [Related]
25. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
26. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
28. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides.
Mao X; Lillington D; Scarisbrick JJ; Mitchell T; Czepulkowski B; Russell-Jones R; Young B; Whittaker SJ
Br J Dermatol; 2002 Sep; 147(3):464-75. PubMed ID: 12207585
[TBL] [Abstract][Full Text] [Related]
29. Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.
Iqbal J; Amador C; McKeithan TW; Chan WC
Cancer Treat Res; 2019; 176():31-68. PubMed ID: 30596212
[TBL] [Abstract][Full Text] [Related]
30. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
31. Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome
Netchiporouk E; Gantchev J; Tsang M; Thibault P; Watters AK; Hughes JM; Ghazawi FM; Woetmann A; Ødum N; Sasseville D; Litvinov IV
Oncotarget; 2017 Nov; 8(56):95981-95998. PubMed ID: 29221181
[No Abstract] [Full Text] [Related]
32. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
[TBL] [Abstract][Full Text] [Related]
33. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the 2008 World Health Organization classification for non-mycosis fungoides, non-Sezary syndrome T/NK-cell lymphomas with primary cutaneous involvement.
Chang D; Zerbini MCN; Sotto MN; Siqueira SAC; Sanches JA
J Cutan Pathol; 2015 Dec; 42(12):965-973. PubMed ID: 26268415
[TBL] [Abstract][Full Text] [Related]
35. [Epidermotropic T cell lymphomas as models for tumor progression].
Bagot M; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
[TBL] [Abstract][Full Text] [Related]
36. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
38. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
39. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
Chevret E; Merlio JP
J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
[TBL] [Abstract][Full Text] [Related]
40. Clonal disease in extracutaneous compartments in cutaneous T-cell lymphomas. A comparative study between cutaneous T-cell lymphomas and pseudo lymphomas.
Dommann SN; Dommann-Scherrer CC; Dours-Zimmermann MT; Zimmermann DR; Kural-Serbes B; Burg G
Arch Dermatol Res; 1996 Apr; 288(4):163-7. PubMed ID: 8967786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
